The antibody-drug conjugate field continues to grow, while antibody-oligonucleotide conjugates are creating new opportunities for targeted delivery. That is why Synoligo will be at the 17th World ADC in San Diego, October 13–14.

Whether your organization is entering the AOC space or advancing candidates already in the pipeline, our team can support your program with custom oligonucleotide synthesis, conjugation, and integrated in vitro screening.

By bringing these capabilities together in one workflow, Synoligo can help accelerate development from sequence design and synthesis through lead candidate selection in as fast as 12 weeks.

Connect with our team at World ADC to discuss your AOC or oligonucleotide program.

#WorldADC #AOC #ADC #Bioconjugation #OligonucleotideTherapeutics #Synoligo